Sir,

I read with interest the paper on Isoniazid induced cerebellitis by Shah VS and Sardana V in the recent AIAN journal. The authors described a patient with chronic renal disease, on 375 mg of isoniazid without pyridoxine supplements, who developed cerebellar toxicity. His MRI showed classical dentate signal changes and he made clinical and radiological recovery following withdrawal of isoniazid and addition of pyridoxine. Certainly, the paper is an important reminder for clinicians to be cautious of this complication in renal disease. However, two statements in the discussion section could confuse the clinicians on the appropriate dose of isoniazid in renal disease. The authors initially, and rightly, state that no dose modification of isoniazid is needed in renal disease. But, in the concluding remarks, they infer from this particular case that a dose modification of ‘anti tubercular drugs’ is indeed needed.

A literature search revealed that the available guidelines advise no dose modification of isoniazid in patients with renal disease, even if they are on hemodialysis. Similarly, no dose modification is needed for rifampicin, pyrazinamide, moxifloxacin and linezolid. Ethambutol can be given in standard doses in stage 1 to 3 Chronic Kidney Disease (CKD) and in patients on hemodialysis, but in stage 4 and 5, 15–25 mg/kg 3×/week (maximum 2.5  g) is recommended. Specific dosing guidelines for other drugs are also available. All drugs need to be given 4–6 hours before the scheduled hemodialysis or after the completion of hemodilaysis. Adherence to the standard guidelines minimizes the risk of drug toxicities as well as under treatment of this serious infection.

To conclude, clinicians can safely use the standard dose of isoniazid in renal disease, which is 5 mg/kg/day, with a maximum of 300 mg/day.

Sir,

Tay–Sachs disease (TSD) is one of the common glycolipid storage disorders with an incidence of 1 in 100,000 live births. TSD (OMIM # 272800) is a result of biallelic pathogenic variants in the HEXA gene that causes deficiency in β-hexosaminidase A (HexA) enzyme (EC 3.2.1.52). This is further categorized into a classic infantile form, sub-acute juvenile form, and late-onset form, depending on the age of onset of symptoms. Notably, India has a TSD case mostly with the infantile phenotype whereas juvenile or late-onset forms have been rarely reported.

Here we describe the second case of juvenile TSD from India along with a review of previously reported juvenile TSD cases having confirmed genetic study.

The proband is the first child born to a non-consanguineous couple and was referred to us at 12 years of age. He had a normal development till the age of 5 years and progressive deterioration of the learned skill with bilateral tremors thereafter. On presentation at our centre, he had gait ataxia, difficulty in climbing stairs, slurred speech, difficulty in getting up and down. Magnetic Resonance Imaging (MRI) scans of
the brain showed mild cortical atrophic changes [Figure 1]. On eye examination, cherry red spot was absent. An IQ assessment study showed IQ level to be 33.3. The clinical presentation suggested a neurodegenerative disorder with a strong suspicion of TSD. Our differentials included Sandhoff disease, neuronal ceroid lipofuscinosis, Friedreich ataxia and late-onset spinal muscular atrophy.

To confirm the clinical diagnosis, a lysosomal enzyme β-hexosaminidase A study was carried out from the leucocytes. The test showed β-hexosaminidase A activity to be 3.1 nmol/hr/mg protein, which was less than 10% of the normal range (62.7–659.4 nmol/hr/mg protein). Further, genomic DNA extracted from blood sample was used to carry out neurology gene panel study. This identified a compound heterozygous variant c.1496G>A (chr15-72637817) (p.Arg499His) in exon 13 and c.902T>G (chr15-72641504) (p.Met301Arg) in exon 8 of the HEXA gene. As per ACMG guidelines, these variants were classified as pathogenic and likely pathogenic, respectively. The results were validated in the proband and both parents by bidirectional sequencing of the coding region of the HEXA gene (ENST00000268097). This study confirmed the presence of both variants in compound heterozygous state in the proband and heterozygous state in both parents.

The juvenile form of TSD is a rare and progressive neurodegenerative disorder with a heterogeneous clinical course.[3] To date, 155 cases of juvenile TSD have been reported in the literature including a single case from India.[4] The mean age of onset was 5.24 ± 3.9 years. We found that dysarthria and gait ataxia are the most common clinical signs, seen in 96.5% and 93.1% of the cases, respectively.[3,5‑9] In the present case also, there was a similar observation with an additional sign of bilateral tremors in hand at 5 years of age which has been seen in only 26.72% of the previously reported cases.[3]

The MRI findings showing cortical atrophy in our case are consistent with those observed in other juvenile TSD cases. Sandhoff et al.[10] have suggested an inverse correlation between the heterogeneity of onset and the residual activity of the β-hexosaminidase enzyme.[10] Patients with the juvenile forms of TSD may have 5-10% of wild-type enzyme activity that lies in the range of 2 to 9 nmol/hr/mg protein.[3,5‑9] Though, previous large study of infantile cases and present case of juvenile TSD could not find a correlation between enzyme activity and the onset of disease.[2] In the present case, this could be due to presence of one heterozygous variant (c.902T>G) which is commonly associated with infantile TSD.
On literature review, we found, forty-one variants in HEXA to be observed with juvenile TSD [Table 1, Figure 2]. The two most common variants found in juvenile TSD are c.1496G>A (p.Arg499His) and c.533G>A (p.Arg178His) found in exon 13 and 5, respectively, in 25.4% of the 67 patients including the present case.\[3,5‑9\]

Both variants in the present case: c.1496G>A (p.Arg499His) and c.902T>G (p.Met301Arg) have been previously reported in the literature in multiple ethnicities. Interestingly, c.1496G>A has been observed in affected TSD patients from various ethnic backgrounds like Caucasian, Argentinean, Portuguese and Italian populations.\[1,7‑9\]

This variant is located outside the catalytic domain, and hence causes minor structural changes, which explains the late-onset clinical phenotype. While the other variant, c.902T>G (p.Met301Arg), has been reported only twice in the literature for infantile TSD. In one case, it was in homozygous state, whereas in another case, it was present in combination with another pathogenic HEXA variant p.Arg504His. This variant is located in the catalytic domain of the α-subunit of β-hexosaminidase A. Although the effect of this variant on the enzyme is unclear, it has

### Table 1: Review of molecularly proven cases of juvenile TSD

| Exon/Intron | Variant       | Type of variant | Ethnicity                      | Percentage of juvenile TSD patients with the variant |
|------------|---------------|-----------------|--------------------------------|------------------------------------------------------|
| Exon 1     | c.1A>T (p.M1L) | Start loss      | Multiple Ethnic Groups         | 1.5%                                                 |
| Exon 1     | c.1A>G (p. M1V) | Start loss      | African-American               | 1.5%                                                 |
| Exon 1     | c.10T>C (p.S4P) | Missense        | Multiple Ethnic Groups         | 1.5%                                                 |
| Exon 1     | c.32T>C (p.L11P) | Missense      | Japanese                       | 1.5%                                                 |
| Exon 1     | c.155C>A (p.S22X) | Nonsense      | Spanish/Portuguese             | 1.5%                                                 |
| Exon 1     | c.77G>A (p.W26X) | Nonsense      | Multiple Ethnic Groups         | 3%                                                   |
| Exon 1     | c.78G>A (p.W26X) | Nonsense      | Cyprus                         | 1.5%                                                 |
| Exon 1     | c.109T>A (p.Y37N) | Missense      | Multiple Ethnic Groups         | 3%                                                   |
| Exon 1     | c.173G>A (p.C58Y) | Missense      | NA                             | 1.5%                                                 |
| Exon 3     | c.409C>T (p.R137X) | Nonsense      | Multiple Ethnic Groups         | 4.5%                                                 |
| Intron 4   | c.459+5G>A     | Non-Coding     | Spanish                        | 3%                                                   |
| Exon 5     | c.509G>A (p.R170Q) | Missense      | NA                             | 1.5%                                                 |
| Exon 5     | c.533G>A (p.R178H) | Missense      | Multiple Ethnic Groups         | 25.4%                                                |
| Exon 5     | c.536A>G (p.H179R) | Missense      | Spanish                        | 1.5%                                                 |
| Exon 5     | c.566G>A (p.R189H) | Missense      | NA                             | 3%                                                   |
| Intron 5   | c.571_1G>T     | Splicing       | Japanese                       | 1.5%                                                 |
| Intron 6   | c.672+1G>A     | Splicing       | Multiple Ethnic Groups         | 3%                                                   |
| Exon 7     | c.681C>A (p.Y227X) | Missense      | NA                             | 1.5%                                                 |
| Exon 7     | c.736_737delG (p.A246R) | Missense | Spanish                        | 1.5%                                                 |
| Exon 7     | c.736G>A (p.A246T) | Missense      | Korean                         | 1.5%                                                 |
| Exon 7     | c.749G>A (p.G250D) | Missense      | Lebanese Maronite              | 1.5%                                                 |
| Exon 7     | c.772G>C (p.D258H) | Missense      | NA                             | 1.5%                                                 |
| Exon 7     | c.805G>A (p.G269S) | Missense      | Multiple Ethnic Groups         | 9%                                                   |
| Exon 8     | c.814G>A (p.G272R) | Missense      | West Indian Origin             | 1.5%                                                 |
| Exon 8     | c.902T>G (p.M301R) | Missense      | Multiple Ethnic Groups         | 1.5%                                                 |
| Exon 8     | c.972T>A (p.V324V) | Synonymous    | Multiple Ethnic Groups         | 1.5%                                                 |
| Exon 9     | c.1003A>T (p.I335F) | Missense      | Spanish/Portuguese             | 1.5%                                                 |
| Intron 9   | c.1073+1G>A     | Splicing       | Spanish                        | 6%                                                   |
| Intron 10  | c.1146+1G>A     | Splicing       | Spanish                        | 1.5%                                                 |
| Exon 11    | c.1195A>G (p.N399D) | Missense      | West Indian Origin             | 1.5%                                                 |
| Exon 11    | c.1274_1277dupTATC (p.Y427X) | Nonsense | Multiple Ethnic Groups         | 17.9%                                                |
| Exon 11    | c.1281T>A (p.Y427X) | Nonsense      | India                          | 1.5%                                                 |
| Exon 11    | c.1305C>T (p.Y435Y) | Synonymous    | Multiple Ethnic Groups         | 6%                                                   |
| Exon 12    | c.1382G>T (p.G461V) | Missense      | Multiple Ethnic Groups         | 3%                                                   |
| Intron 12  | c.1421+5G>C     | Non-coding     | Spanish                        | 1.5%                                                 |
| Exon 13    | c.1422G>C (p.W474C) | Missense      | German-Dutch                   | 3%                                                   |
| Exon 13    | c.1496G>A (p.R499H) | Missense      | Multiple Ethnic Groups         | 25.4% (*Present case)                                 |
| Exon 13    | c.1495C>T (p.R499C) | Missense      | NA                             | 3%                                                   |
| Exon 13    | c.1511G>A (p.R504H) | Missense      | Multiple Ethnic Groups         | 4.5%                                                 |
| Exon 13    | c.1511G>T (p.R504L) | Missense      | Argentina                      | 1.5%                                                 |
| Exon 14    | c.1529_1530del (p.R510H) | Missense | India                          | 1.5%                                                 |
been hypothesized that the association process of the two subunits (\(\alpha\) and \(\beta\)) of the enzyme might be affected.[11]

Thus, based on the reported cases in the literature and present case, it is likely possible to predict the onset of symptoms and the disease severity depending on the mutation in \(HEXA\) gene and its subsequent effect on the residual \(\beta\)-hexosaminidase A activity. Hence, establishing genotype-phenotype correlation is critical to understand the patient prognosis and plan effective management of the condition.

Present case highlights the rarity of juvenile TSD in India and shows bilateral tremors as an early sign in this condition. The variant c.902T>G in the \(HEXA\) has been reported in infantile forms of TSD. Nonetheless, due to presence of c.1496G>A, a common variant in juvenile TSD, the index case has shown a milder phenotype with juvenile onset.

Acknowledgements
We express our thanks to the patient and his parents for their cooperation. We thank Dr. Heli Shah for referring this case. We also thank Dr. Harsh Sheth for his partial help in the reading and making critical suggestions for the manuscript.

Financial support and sponsorship
This work was partly supported by Gujarat State Biotechnology Mission (GSBTM) (grant no: GSBTM/JDR &/D/608/2020/459-461).

Conflicts of interest
There are no conflicts of interest.

Jayesh Sheth, Ira Mohapatra, Gangotri Patra, Riddhi Bhavsar, Chandni Patel, Siddharth Shah, Aadhira Nair
Department of Biochemical and Molecular Genetics, FRIGE’s Institute of Human Genetics, FRIGE House, Jodhpur Gam Road, Satellite, Ahmedabad, ‘Consultant Pediatric Neurologist, Royal Institute of Child Neurosciences, Vastrapur, Ahmedabad, Gujarat, India

Address for correspondence: Dr. Jayesh Sheth, Biochemical Genetics, FRIGE House, Jodhpur Gam Road, Satellite, Ahmedabad - 380 015, Gujarat, India.
E-mail: jayesh.sheth@frige.co.in

References
1. Lew RM, Burnett L, Proos AL, Delatycki MB. Tay-Sachs disease: Current perspectives from Australia. Appl Clin Genet 2015;8:19-25.
2. Mistri M, Tamhankar PM, Sheth F, Sanghavi D, Kondurkar P, Patil S, et al. Identification of novel mutations in \(HEXA\) gene in children affected with tay sachs disease from India. PLoS One 2012;7:e39122.
3. Maegawa GH, Stockley T, Tropak M, Banwell B, Blaser S, Kok F, et al. The natural history of juvenile or subacute GM2 gangliosidosis: 21 new cases and literature review of 134 previously reported. Pediatrics 2006;118:e1550-62.
4. Udwalla-Hegde A, Hajirnis O. Temporary efficacy of pyrimethamine in Juvenile-Onset Tay-Sachs disease caused by 2 unreported \(HEXA\) mutations in the Indian population. Child Neurol Open 2017;4:2329048X16687887.
5. Smith NJ, Winstone AM, Stellitano L, Cox TM, Verity CM. GM2 gangliosidosis in a UK study of children with progressive neurodegeneration: 73 cases reviewed. Dev Med Child Neurol 2012;54:176-82.
6. Sakurai M, Azuma J, Hamada Y, Yamamoto T, Sakai N. Early juvenile Tay-Sachs disease with atypical symptoms. Pediatr Int 2019;61:611-3.
7. Rozenberg R, Kok F, Burin MG, Sâ Miranda MC, Vasques C, Henriques-Souza AMM, et al. Diagnosis and molecular characterization of non-classic forms of Tay-Sachs disease in Brazil. J Child Neurol 2006;21:540-4.
8. Ou L, Kim S, Whitley CB, James-Utz JR. Genotype-phenotype correlation of gangliosidosis mutations using in silico tools and homology modeling. Mol Genet Metab Rep 2019;20:100495.
9. King KE, Kim S, Whitley CB, James-Utz JR. The juvenile gangliosidoses: A timeline of clinical change. Mol Genet Metab Rep 2020;25:100676.
10. Sandhoff K. My journey in to the world of Sphingolipids and Sphingolipidosis. Proc Jpn Acad Ser B Phys Biol Sci. 2012;88(10):554-582.
11. Cheema H, Bertoli-Avella AM, Skrahina V, Anjum MN, Waheed N, Saeed A, et al. Genomic testing in 1019 individuals from 349 Pakistani families results in high diagnostic yield and clinical utility. NPJ Genom Med 2020;5:44.

Submitted: 22-Jun-2021 Revised: 11-Aug-2021 Accepted: 25-Aug-2021 Published: 05-Jan-2022

This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

DOI: 10.4103/aiian.aiian_577_21